NavalGustadDaverMD

PubMed

• Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
  Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel, Koichi Takahashi, Prithviraj Bose, John Villarreal, Sherry Pierce, Tapan Kadia, ...> ;American Journal of Hematology. 2024 Apr 13
• Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
  Wei-Ying Jen, Wei Qiao, Farhad Ravandi, Koji Sasaki, Sanam Loghavi, Sa A Wang, Gautam Borthakur, Tapan M Kadia, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Naval G D...> ;British Journal of Haematology. 2024 Apr 11
• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
  Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
• Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
  Naval G Daver, Charles Craddock> ;Journal of Clinical Oncology. 2024 Mar 12
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• 1 citations
  Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
  Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
• Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.
  Garcia, M. B., Bofei Wang, Patrick K Reville, Mhd Yousuf Yassouf, Fatima Z Jelloul, Christopher Ly, Poonam N Desai, Zhe Wang, Pamella Borges, Ivo Veletic, Enes Dasdemi...> ;Nature Communications. 2024 Feb 28
• Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia.
  Shengnan Guo, Gopi S Mohan, Bofei Wang, Tianhao Li, Naval Daver, Yuting Zhao, Patrick K Reville, Dapeng Hao, Hussein A Abbas> ;Journal for Immunotherapy of Cancer. 2024 Feb 28
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
• Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
  Jessica L Root, Poonam N Desai, Christopher Ly, Bofei Wang, Fatima Zahra Jelloul, Jing Zhou, Sean Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Patrick K Rev...> ;Cancer Research Communications. 2024 Mar 6
• BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
  Warren Fiskus, Jessica Piel, Michael P Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine Birdwell, Kaberi Das, John A Davis, Hanxi Hou, Antrix...> ;Blood. 2024 Feb 16
• Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
  Pasvolsky, O., Saliba, R., Popat, U., Alousi, A., Mehta, R., Yeh, J., Al-Atrash, G., Adeel, M., Ramdial, J., Marin, D., Rondon, G., Kebriaei, P., Champlin, R., Daver, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• 1 citations
  Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
  Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
• Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
  Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
• Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
• Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
  Konopleva, M., Dail, M., Daver, N., Garcia, J., Jonas, B., Yee, K., Kelly, K., Vey, N., Assouline, S., Roboz, G., Paolini, S., Pollyea, D., Tafuri, A., Brandwein, J., ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 18
• Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
  Nishanthan Rajakumaraswamy, Mitul Gandhi, Andrew H Wei, David A Sallman, Naval G Daver, Shuyuan Mo, Shahed Iqbal, Roshan Karalliyadda, Manli Chen, Yunfei Wang, Paresh ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Apr 1
• 1 citations
  Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
  Bataller, A., Bazinet, A., DiNardo, C., Maiti, A., Borthakur, G., Daver, N., Short, N., Jabbour, E., Issa, G., Pemmaraju, N., Yilmaz, M., Montalban-Bravo, G., Takahash...> ;Blood Advances. 2024 Feb 27
• Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
  Birdwell, C., Fiskus, W., Kadia, T., Mill, C., Sasaki, K., Daver, N., DiNardo, C., Pemmaraju, N., Borthakur, G., Davis, J., Das, K., Sharma, S., Horrigan, S., Ruan, X....> ;Leukemia. 2024 Mar 1
• Novel immunotherapies in the treatment of AML: is there hope?
  Subklewe, M., Bücklein, V., Sallman, D., Daver, N.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
• 1 citations
  Enhancedreactivation disruptstranscriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
  Yuki Nishida, Jo Ishizawa, Edward Ayoub, Rafael Heinz Montoya, Lauren B Ostermann, Muharrem Muftuoglu, Vivian R Ruvolo, Tallie Patsilevas, Darah A Scruggs, Shayaun Kha...> ;Science Advances. 2023 Dec 1
• Join now to see all

Abstracts/Posters

• Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE¬ Antibody Construct
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and ...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML
  Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia... 
  2019 ASCO Annual Meeting - 6/1/2019
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all